4Vote!
Medical News Today (Free subscription) | 11 hours ago
Lorus Therapeutics Inc. (TSX:LOR) ("Lorus" or the "Corporation"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, announced that its Phase II clinical trial in refractory and relapsed AML with LOR-2040 in combination with cytarabine has been successfully completed to the end-of-stage...
+Vote!
Medical News Today (Free subscription) | 11 hours ago
Cytokinetics, Incorporated (NASDAQ: CYTK) announced that a poster and oral presentation summarizing non-clinical data regarding CK-2017357, a fast skeletal troponin activator, are scheduled to be presented at the 5th Cachexia Conference, organized by the Society on Cachexia and Wasting Disorders, being held December 5-8, 2009 at the Princesa Sofia Hotel in Barcelona, Spain.
+Vote!
Medical News Today (Free subscription) | yesterday
arGentis Pharmaceuticals, LLC announced that it will collaborate with the University of Tennessee Health Science Center (UTHSC) and the Veterans Affairs Medical Center of Memphis (VAMC) to initiate the first human clinical evaluation of an oral altered peptide ligand (APL), ARG301, in a Phase I study of Rheumatoid Arthritis patients. ARG301 is a synthetic peptide, which in animal studies appears to...
4Vote!
Medical News Today (Free subscription) | 29/11/2009
The Swedish biotech company Karo Bio (Reuters: KARO.ST) announced that Merck & Co., Inc., through an affiliate, plans to enter a clinical phase IIa trial with the collaboration's lead investigational drug candidate, MK-6913, identified as part of their joint research collaboration. No milestone payment to Karo Bio is associated with the initiation of phase II clinical development.
4Vote!
Medical News Today (Free subscription) | 27/11/2009
An innovative treatment for HIV patients developed by McGill University Health Centre researchers has passed its first clinical trial with flying colours. The new approach is an immunotherapy customized for each individual patient, and was developed by Dr. J-P. Routy from the Research Institute of the MUHC in collaboration with Dr. R. Sékaly from the Université de Montréal.
+Vote!
Medical News Today (Free subscription) | 26/11/2009
SNM will hold its Conjoint Mid-Winter Meetings Jan. 27-Feb. 2, 2010, at the Albuquerque Convention Center in Albuquerque, N.M. This year, SNM joins its annual Mid-Winter Educational Symposium with the 2010 Annual Meeting and Educational Symposium of the American College of Nuclear Medicine (ACNM), the Nanomedicine and Molecular Imaging Summit and the Clinical Trials Network Community Workshop.
4Vote!
Medical News Today (Free subscription) | 25/11/2009
UK-based Synexus, the world's largest multi-national company dedicated to the recruitment and running of clinical trials, recruited the highest number of patients to the South African study investigating a paediatric vaccine against rotavirus. The company recruited more than 2000 children aged between 5 and 10 weeks in 3 months, making Synexus the largest single source of subjects for this Phase III...
4Vote!
Medical News Today (Free subscription) | 25/11/2009
OmniComm Systems, Inc. (OTCBB: OMCM), one of the fastest growing companies in the EDC marketplace, announced that Beardsworth, a full service contract research organization (CRO) who specializes in difficult therapeutic areas, has selected OmniComm's TrialMaster EDC solution for conducting a Phase II vaccine study. The 3-year, 10-site study is planning to enroll 340 subjects. "After a careful...
4Vote!
Medical News Today (Free subscription) | 25/11/2009
Asthma is the commonest chronic disease in children and a major reason for admissions to hospital, yet inadequate asthma control is present in 26% to 45% of children, states a review http://www.cmaj.ca/embargo/cmaj071638.pdf in CMAJ (Canadian Medical Association Journal).
4Vote!
Medical News Today (Free subscription) | 24/11/2009
Women who store fat on their waist in middle age are more than twice as likely to develop dementia when they get older, reveals a new study from the Sahlgrenska Academy. The study has just been published in the scientific journal Neurology. "Anyone carrying a lot of fat around the middle is at greater risk of dying prematurely due to a heart attack or stroke," says Deborah Gustafson, senior...
3Vote!
Rocky Mount Telegram - Business (Free subscription) | 23/11/2009
NEW YORK — Pharmasset Inc. said Monday that it will continue enrolling patients in a clinical ...
4Vote!
Medical News Today (Free subscription) | 23/11/2009
POZEN Inc. (NASDAQ: POZN) announced the start of enrollment for the phase 3 studies for PA32540. PA32540 is a fixed-dose combination of 325 mg of enteric coated aspirin and 40 mg of immediate release omeprazole, under investigation for use in the secondary prevention of heart attacks and strokes in patients at risk for associated gastric ulcers.
4Vote!
Medical News Today (Free subscription) | 23/11/2009
ImmuPharma PLC announced the final results from a Phase IIb trial of LUPUZOR™ in active patients with Systemic Lupus Erythematosus (SLE). Lupuzor™ administered at 200 mcg once-a-month for 3 months plus standard of care achieved a clinically significant improvement in patient response rate as measured by the combined score compared to placebo plus standard of care.
4Vote!
Medical News Today (Free subscription) | 23/11/2009
Treatment that includes medication plus a structured training program for parents reduces serious behavioral problems in children with autism and related conditions, according to a study funded by the National Institute of Mental Health (NIMH). The study, which was part of the NIMH Research Units on Pediatric Psychopharmacology (RUPP) Autism Network, was published in the December 2009 issue of the...
4Vote!
Medical News Today (Free subscription) | 23/11/2009
A pediatric immunologist at The Children's Hospital of Philadelphia has received a prestigious annual award from the American Philosophical Society, an organization founded in 1743 by Benjamin Franklin. Jordan S. Orange, M.D., Ph.D., received the Society's Judson Daland Prize for his contributions to research and treatment of inherited immune deficiency diseases. The Judson Daland Prize for Clinical...